期刊文献+

药物经济学评价Markov模型实例解析 被引量:1

Instance analysis of Markov model for pharmacoeconomics evaluation
原文传递
导出
摘要 目的:本文旨在对已建立的Markov模型进行解析,为中国胃癌治疗方案的药物经济学研究奠定基础。方法:深入分析Markov模型建立的理由和方法。结果:胃癌治疗后的自然转归符合Markov基本原理,可划分为三种互不相容的生存状态,合理假设可简化Markov模型,转移概率是Markov模型是否正确的关键。结论:对中国胃癌患者两种治疗方案进行药物经济学评价,可采用划分3种互不相容健康状态,使用TreeAge软件创建Markov模型,利用公开发表的大型Ⅲ期临床试验结果,结合WHO生命表数据确定转移概率,以此创建切实可行的Markov模型。 OBJECTIVE To analyze the established Markov model instances and provide a research foundation of pharmaco economics for therapeutic regimen of stomach cancer in China. METHODS Based on reasons and methods of built models, a detailed explanation was given+ RESULTS Basic principle of Markov model was fitted by natural outcome after treatment a- gainst gastric cancer. Three incompatible states of survival could be divided for gastric cancer patients. Reasonable assumptions could simplify Markov model. Transition probabilities were keys of valid Markov model. CONCLUSION For pharmacoeconom- ic evaluation of two remedies for Chinese gastric cancer patients, three incompatible health states can be used. A perfect Mark ov model can be established by software TreeAge, using published phase [lI of clinical trial results and calculating transition probabilities partly from WHO life table.
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2015年第18期1690-1693,共4页 Chinese Journal of Hospital Pharmacy
基金 国家自然科学基金(编号:81173028)
关键词 胃癌 MARKOV模型 药物经济学 gastric cancer markov model pharmacoeconmics
  • 相关文献

参考文献4

二级参考文献114

  • 1李幼平.药物经济学与循证医学[J].中国药物经济学,2008,0(6):14-19. 被引量:5
  • 2王施益,李洪超.对我国高校药物经济学教育开展情况的调查[J].中国药物经济学,2008,3(4):49-61. 被引量:11
  • 3杨莉,胡善联,陈文.成本效果比五种可信区间估计法比较[J].中国卫生统计,2004,21(3):150-153. 被引量:5
  • 4曹燕.决策分析模型在药物经济学中的应用[J].中国药房,2007,18(8):561-564. 被引量:32
  • 5STOKES ME, THOMPSON D, MONTOYA EL, et al. Ten-year survival and cost following breast cancer recurrence: estimates from SEER-medicare data[J]. Value Health, 2008, 11 (2): 213- 220.
  • 6MARTIN M, PIENKOWSKI T, MACKEY J, et ol. Adjuvant docetaxel for node-positive breast cancer [J]. N Engl J Med, 2005, 352(22): 2302-2313.
  • 7AU HJ, GOLMOHAMMADI K, YOUNIS T, et ol. Costeffectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects [J]. Breast Cancer Res Treat, 2009, 114(3) : 579-587.
  • 8WOLOWACZ SE, CAMERON DA, TATE HC, et al. Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a costeffectiveness and cost-utility analysis[J]. J Clin Oncol, 2008, 26 (6) : 925-933.
  • 9LEE SG, JEE YG, CHUNG HC, et ol. Cost-effectiveness analysis of adjuvant therapy for node positive breast cancer in Korea : docetaxel, doxorubicin and cyclophosphamide (TAC) versus fluorouracil, doxorubicin and cyclophosphamide (FAC) [J]. Breast Cancer Res Treat, 2009, 114 (3) : 589-595.
  • 10SONNENBERG FA, BECK JR. Markov models in medical decision making: a practical guide [J]. Med Decis Making, 1993, 13(4): 322-338.

共引文献311

同被引文献4

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部